Treatment of renal disorders, diabetic nephropathy and dyslipidemias

• US 8,372,886 B2
• Filed: 12/22/2006
• Issued: 02/12/2013
• Est. Priority Date: 12/22/2005
• Status: Active Grant

• Current Assignee: Kiacta Sarl
• Original Assignee: Kiacta Sarl
• Inventors: Hauck, Wendy, Hamet, Pavel
• Primary Examiner(s): Padmanabhan, Sreeni
• Assistant Examiner(s): Betton, Timothy E
• Application Number:
  US11/643,946
• Publication Number:
  US 20070238788A1
• Time in Patent Office: 2,244 Days
• Field of Search: 514/553
• US Class Current: 514/578
• CPC Class Codes: A61K 31/10 Sulfides; Sulfoxides; Sulfones
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

Disclosed herein are methods, compounds and compositions for preventing or treating a renal disorder or chronic kidney diseases, including nephropathies such as diabetic nephropathy. The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for the prevention and/or treatment of for preventing or treating a renal disorder complication. The invention further relates to methods, compounds and compositions for the prevention and/or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in diabetic patients.

Claims

1. A method for treating diabetic nephropathy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein said compound is 1,3-propanedisulfonic acid sodium salt.

3. The method of claim 1, wherein clearance of creatinine and/or clearance of uric acid is improved in the subject subsequent to said administration.

4. The method of claim 2, wherein said compound is 1,3-propanedisulfonic acid disodium salt.

5. The method of claim 2, wherein clearance of creatinine and/or clearance of uric acid is improved in said subject subsequent to said administration.

6. The method of claim 2, wherein said subject does not have amyloidosis.

7. The method of claim 6, wherein said subject does not have AA-amyloidosis.

8. The method of claim 3, wherein said compound is 1,3-propanedisulfonic acid sodium salt.

9. The method of claim 8, wherein said compound is 1,3-propanedisulfonic acid disodium salt.

10. The method of claim 3, wherein said subject does not have amyloidosis.

11. The method of claim 10, wherein said subject does not have AA-amyloidosis.

12. The method of claim 1, wherein said wherein said subject does not have amyloidosis.

13. The method of claim 12, wherein said subject does not have AA-amyloidosis.

14. The method of claim 12, wherein said compound is 1,3-propanedisulfonic acid sodium salt.

15. The method of claim 14, wherein said compound is 1,3-propanedisulfonic acid disodium salt.

16. The method of claim 12, wherein clearance of creatinine and/or clearance of uric acid is improved in said subject subsequent to said administration.

17. The method of claim 1, wherein said subject does not have AA-amyloidosis.

18. The method of claim 17, wherein clearance of creatinine and/or clearance of uric acid is improved in said subject subsequent to said administration.

19. The method of claim 17, wherein said compound is 1,3-propanedisulfonic acid sodium salt.

20. The method of claim 19, wherein said compound is 1,3-propanedisulfonic acid disodium salt.

21. The method of claim 1, wherein said compound is 1,3-propanedisulfonic acid disodium salt.

22. The method of claim 21, wherein clearance of creatinine and/or clearance of uric acid is improved in said subject subsequent to said administration.

23. The method of claim 21, wherein said subject does not have amyloidosis.

24. The method of claim 23, wherein said subject does not have AA-amyloidosis.

25. The method of claim 1, wherein said therapeutically effective amount is 400 mg, 800 mg or 1,200 mg BID.